BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of BlossomHill Therapeutics (NASDAQ:BLSM) from a hold rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Several other research firms also recently commented on BLSM. Leerink Partners lifted their price objective on BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. Guggenheim upped their target price on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, September 21st. JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price target on the stock. Lifesci Capital initiated coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price target for the company. Finally, Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Trading Up 5.9%

BLSM stock opened at $19.69 on Friday. The company has a 50 day simple moving average of $19.89. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM) last posted its earnings results on Friday, September 18th. The company reported ($8.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). As a group, analysts forecast that BlossomHill Therapeutics will post -5.54 EPS for the current year.

Insider Buying and Selling

In other news, Director John P. Schmid bought 6,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average price of $16.00 per share, with a total value of $96,000.00. Following the completion of the acquisition, the director owned 6,000 shares in the company, valued at $96,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Carl L. Gordon bought 625,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. The trade was a 29.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 1,573,900 shares of company stock valued at $25,181,900 over the last ninety days.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.